What raloxifene dose do labels and studies give for gynecomastia?

Supply: tablets
ProductStrengthSupplied
Evista tablet for oral use160 mg, film-coatedBottles of 30

The Evista label gives a 60 mg tablet orally once daily for its indications in postmenopausal women and says there is no indication for its use in men, and a 2010 crossover study in ten healthy men by Birzniece and colleagues used raloxifene 60 and 120 mg/d, while the one gynecomastia study the pack's searches found, a 2004 chart review of 38 patients with persistent pubertal gynecomastia by Lawrence and colleagues, gives no raloxifene dose in its published summary.123

Supply: tablets

The table is set at the top of the page

The label describes a tablet for oral use, with no powder or mixing step.1 Every raloxifene label the pack's DailyMed search listed is a tablet, so the sources give no concentration per mL and no syringe mark for a raloxifene dose.

Label dose and doses used in men

The Evista label gives a 60 mg tablet orally once daily, for indications that are all in postmenopausal women.1 Its Medication Guide says to take it at any time of day, with or without food.1 The table lists the trials in men the pack's searches found, none of which treated gynecomastia.

TrialDose and schedulePeopleLength
Duschek and colleagues, 20044120 mg/dayThirty healthy men aged 60 to 70, double-blind against placebo (n=15 each)3 months
Birzniece and colleagues, 2010260 and 120 mg/dTen healthy men, randomized open-label crossover with tamoxifen 10 and 20 mg/d2-wk sequential treatment, 2-wk washout
Smith and colleagues, 2004560 mg/d48 men with nonmetastatic prostate cancer on a GnRH agonist, open-label against no raloxifene12 months
Lee and colleagues6120 mg (two 60 mg tablets) with cholecalciferol 1,600 IU, as fixed-dose combination tablets or as separate tablets46 healthy male volunteers, crossover between the twoSingle dose

Gynecomastia, on cycle and after

The label lists osteoporosis and reduction in risk of invasive breast cancer, both in postmenopausal women, and gynecomastia is not among its indications.1 It says there is no indication for the use of Evista in men, that Evista has not been adequately studied in men and that its use in men is not recommended.1 In a 2004 retrospective chart review, Lawrence and colleagues looked at 38 consecutive patients with persistent pubertal gynecomastia at a pediatric endocrinology clinic, who received reassurance alone or a 3- to 9-month course of tamoxifen or raloxifene; its published summary gives no raloxifene dose.3 Treated patients had a mean (SD) age of 14.6 (1.5) years, and the mean reduction in breast nodule diameter was 2.1 cm after tamoxifen.3 The authors say further study is required to determine that the nodule change is truly a treatment effect.3

Beyond that chart review, searches of DailyMed, PubMed and ClinicalTrials.gov returned no label indication for gynecomastia, bodybuilding, on-cycle or post-cycle use, and no adult-male gynecomastia trial, on cycle or after. Milligram has no logged figure for raloxifene to report.

Duration and safety

The label says the optimum duration of treatment is not known for breast cancer risk reduction, and its Medication Guide says women in clinical trials took Evista for up to eight years.1 The label has a boxed warning on increased risk of venous thromboembolism and death from stroke, the increased risk of death due to stroke having occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events.1 In the MORE trial (Ettinger and colleagues, 1999), 7705 postmenopausal women with osteoporosis were randomized to raloxifene 60 mg/d, 120 mg/d or placebo, with up to 40 months of follow-up for serious adverse events, and women receiving raloxifene had increased risk of venous thromboembolus vs placebo (RR, 3.1; 95% CI, 1.5-6.2).7

Frequently asked questions

How should raloxifene tablets be stored?

The label gives storage at controlled room temperature, 20° to 25°C.1

Is raloxifene established for use in boys?

The label says safety and effectiveness in pediatric patients have not been established.1

References

  1. DailyMed (Eli Lilly). These highlights do not include all the information needed to use EVISTA safely and effectively. See full prescribing information for EVISTA. EVISTA (raloxifene hydrochloride) Tablet for Oral Use Initial U.S. Approval: 1997. 2026. dailymed.nlm.nih.gov
  2. PubMed. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. 2010. pubmed.ncbi.nlm.nih.gov
  3. PubMed. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. 2004. pubmed.ncbi.nlm.nih.gov
  4. PubMed. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. 2004. pubmed.ncbi.nlm.nih.gov
  5. PubMed. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. 2004. pubmed.ncbi.nlm.nih.gov
  6. PMC. A randomized, open-label, single-dose, two-way crossover study to assess the pharmacokinetics between two tablets of fixed-dose combination formulation with raloxifene and cholecalciferol and concomitant administration of each agents in healthy male volunteers. 2022. pmc.ncbi.nlm.nih.gov
  7. PubMed. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. 1999. pubmed.ncbi.nlm.nih.gov